← All trials
NCT00016887
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2000
- Primary completion
- —
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- German Low Grade Lymphoma Study GroupLead sponsor
- University of GroningenStudy chair
- Ospedale Civile AlessandriaStudy chair
- AZ Sint-JanStudy chair
- Gruppo Italiano Studio LinfomiCollaborator
- The Lymphoma Study AssociationCollaborator
- European Organisation for Research and Treatment of CancerCollaborator
- Ludwig Maximilians UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.